<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717195</url>
  </required_header>
  <id_info>
    <org_study_id>16159A</org_study_id>
    <secondary_id>2014-003569-12</secondary_id>
    <nct_id>NCT02717195</nct_id>
  </id_info>
  <brief_title>Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia</brief_title>
  <acronym>DayBreak</acronym>
  <official_title>Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in
      patients with treatment-resistant schizophrenia (TRS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a Screening Period (3 weeks), a single-blind Prospective Confirmation
      (PC) Period (6 weeks), a Double-blind Treatment (DBT) Period (10 weeks), and a Safety
      Follow-up Period (6 weeks).

      Patients who did not fulfil the randomization criteria for the DBT Period, were withdrawn
      from the study after the PC period.

      Patients who fulfilled the randomization criteria for the DBT Period, continued into the DBT
      Period and were randomized into one of 3 treatment arms (1:1:1) with either Lu AF35700 10
      mg/day, Lu AF35700 20 mg/day or to continue the treatment allocated in PC Period (olanzapine
      or risperidone) at the dose set at last visit of PC Period. This mean that approximately one
      third of the confirmed treatment-resistant patients were randomised back to the failed
      treatment used in the PC Period.

      Data was not collected separately for the DBT Olanzapine and DBT Risperidone participants,
      and there was no intent to compare Lu AF35700 to each drug separately.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Randomization to Week 10 in Positive and Negative Syndrome Scale (PANSS) Total Score</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization to Week 10 in PSP Total Personal and Social Performance (PSP) Total Score</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. It consists of 4 items: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviours. Each items were assessed on a 6-point scale, from 1 (absent) to 6 (very severe). PSP score was calculated as sum of all the items on the scale and ranged from 4 to 100. A higher score represents more severe functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization to Week 10 in Global Clinical Impression - Severity of Illness (CGI-S) Score</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 10, Defined as ≥20% Reduction in PANSS Total Score, PANSS (Positive and Negative Syndrome Scale) Total Score ≤70, CGI-S (Clinical Global Impression Scale - Severity of Illness) Score &lt;4</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.
The Clinical Global Impression scale - severity of illness (CGI-S) is administered by the investigator. The patient is rated on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). A reduction in scale indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 10, Defined as ≥20% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 10, Defined as ≥30% Reduction in PANSS Total Score From Randomization</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>Positive and Negative Syndrome Scale (PANSS) total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 10, Defined as ≥40% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at Week 10, Defined as ≥50% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</measure>
    <time_frame>From Randomization to Week 10</time_frame>
    <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1098</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Prospective Confirmation (PC) Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBT Period, Lu AF35700 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBT Period, Continued treatment from PC Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>4-6 mg/day, encapsulated tablets, orally</description>
    <arm_group_label>DBT Period, Continued treatment from PC Period</arm_group_label>
    <arm_group_label>Prospective Confirmation (PC) Period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>15-20 mg/day, encapsulated tablets, orally</description>
    <arm_group_label>DBT Period, Continued treatment from PC Period</arm_group_label>
    <arm_group_label>Prospective Confirmation (PC) Period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700</intervention_name>
    <description>10 mg/day, encapsulated tablets, orally</description>
    <arm_group_label>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700</intervention_name>
    <description>20 mg/day, encapsulated tablets, orally</description>
    <arm_group_label>DBT Period, Lu AF35700 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has schizophrenia, diagnosed according to DSM-5(TM) (Diagnostic and
             Statistical Manual of Mental Disorders) and confirmed by the Mini International
             Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders

          -  The patient is either an inpatient at a psychiatric setting or outpatient consulting a
             psychiatrist.

          -  Patients should be treated with adequate dose(s) and agent(s) of antipsychotic
             treatment for at least 2 weeks prior to Screening

          -  The patient has failed to show an adequate response in the level of psychotic symptoms
             despite at least one documented treatment trial with an adequate dose of an
             antipsychotic agent prescribed for an adequate time (at least lasting for 6 weeks)
             during 2 years prior to Screening. The failure to respond to the current antipsychotic
             treatment trial may be considered a retrospective failed treatment, if the patient was
             treated for 6 weeks with adequate dose(s) and agent(s)

          -  The patient has a PANSS total score of ≥80 and a score of ≥4 on at least 2 of the
             following PANSS items (at Screening and at the first visit of Period A)

          -  The patient has a CGI-S score of ≥4 at Screening and at the first visit of Period A

        Exclusion Criteria:

          -  The patient has any current primary psychiatric disorder other than schizophrenia as
             assessed by the Mini International Neuropsychiatric Interview (MINI)

          -  The patient is experiencing an acute exacerbation of his/her psychotic symptoms

          -  The patient has not responded to treatment with clozapine

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US1018</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1041</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1062</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1463</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1104</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1118</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1114</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1452</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056-4509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1459</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056-4515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1399</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1368</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1391</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92408-3332</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1464</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705-3610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1384</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403-1747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1392</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502-4432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1396</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1395</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1253</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1130</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1318</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1129</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1402</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334-4400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1229</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1453</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609-2231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1403</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1009</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1442</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1046</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1423</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169-1067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1398</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101-4603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1404</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104-2136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1086</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1444</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102-1943</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1426</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1454</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1405</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1244</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1394</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1416</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035-6000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1171</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1190</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1390</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204-3110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1401</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211-1064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1441</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601-5045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1124</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1319</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1451</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754-5122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1065</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1443</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1030</name>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1028</name>
      <address>
        <city>Kazanlak</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1003</name>
      <address>
        <city>Lovech</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1032</name>
      <address>
        <city>Pazardzhik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1008</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1024</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1026</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1022</name>
      <address>
        <city>Tserova Koria</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1033</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1034</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1029</name>
      <address>
        <city>Veliko Tŭrnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1027</name>
      <address>
        <city>Vratsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA1017</name>
      <address>
        <city>Chatham</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA1034</name>
      <address>
        <city>Kingston</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA1003</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA1033</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA1029</name>
      <address>
        <city>Penticton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA1039</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ1023</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ1032</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ1037</name>
      <address>
        <city>Hostivice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ1013</name>
      <address>
        <city>Lnare</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ1038</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EE1016</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EE1007</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EE1017</name>
      <address>
        <city>Viljandi</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI1032</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI1030</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI1027</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1024</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1011</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1021</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1022</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1020</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1005</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1007</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1015</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1016</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MX1018</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1025</name>
      <address>
        <city>Bełchatów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1043</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1026</name>
      <address>
        <city>Gorlice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1060</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1027</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1058</name>
      <address>
        <city>Pruszcz Gdanski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1061</name>
      <address>
        <city>Pruszkow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1059</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1051</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO1024</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO1022</name>
      <address>
        <city>Câmpulung</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO1025</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RO1004</name>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1021</name>
      <address>
        <city>Nikol'skoye</city>
        <state>Gatchinckiy District</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1009</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1006</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1051</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1055</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1023</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1028</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1030</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1031</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1052</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1053</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1056</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1049</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1050</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1008</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1010</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1012</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1011</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1016</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1017</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1003</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS1009</name>
      <address>
        <city>Novi Knezevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK1014</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK1024</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK1015</name>
      <address>
        <city>Roznava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK1025</name>
      <address>
        <city>Svidnik</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK1026</name>
      <address>
        <city>Zlate Moravce</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1047</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1012</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1008</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1048</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1049</name>
      <address>
        <city>Zamora</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1019</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1017</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1022</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1031</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1035</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1028</name>
      <address>
        <city>Kherson</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1029</name>
      <address>
        <city>Kherson</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1027</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1030</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1033</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1020</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1032</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1001</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA1036</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <results_first_submitted>August 30, 2019</results_first_submitted>
  <results_first_submitted_qc>October 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02717195/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02717195/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients who did not fulfil the randomization criteria for the DBT Period, were withdrawn from the study after the PC period. Patients who fulfilled the randomization criteria for the DBT Period, continued into the DBT Period. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prospective Confirmation (PC) Period, Risperidone</title>
          <description>Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
Risperidone: 4-6 mg/day, encapsulated tablets, orally</description>
        </group>
        <group group_id="P2">
          <title>PC Period, Olanzapine</title>
          <description>Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
        </group>
        <group group_id="P3">
          <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
          <description>Lu AF35700: 10 mg/day, encapsulated tablets, orally for 10 weeks</description>
        </group>
        <group group_id="P4">
          <title>DBT Period, Lu AF35700 20 mg</title>
          <description>Lu AF35700: 20 mg/day, encapsulated tablets, orally for 10 weeks</description>
        </group>
        <group group_id="P5">
          <title>DBT Period, Continued Treatment From PC Period</title>
          <description>Patients in this arm will continue the treatment allocated in the PC Period at the dose set at last visit of the PC Period. The analysis is made independent on which treatment the patient was on (risperidone or olanzapine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Prospective Confirmation (PC) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="711"/>
                <participants group_id="P2" count="387"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="276"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with IMP</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not fulfill rand criteria for DBT</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled but not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of results for blood levels</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low level of drug in the blood</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of place of residence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Apato Abulcasis Syndrome</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject took exclusionary medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sub therapeutic blood levels Olanzapine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive Urine Drug Screen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Duplicate subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor requested</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient fraud with payment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Treatment (DBT) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="235"/>
                <participants group_id="P4" count="232"/>
                <participants group_id="P5" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="198"/>
                <participants group_id="P4" count="188"/>
                <participants group_id="P5" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family circumstances</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of residence</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Needed antidepressant medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Psychosocial issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient missed required visits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-randomized Patients</title>
          <description>Patients not randomized into the double-blind treatment period, i.e. withdrawn from the study during or after the PC period, were analyzed as one arm independent of treatment.</description>
        </group>
        <group group_id="B2">
          <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
          <description>Lu AF35700: 10 mg/day, encapsulated tablets, orally for 10 weeks</description>
        </group>
        <group group_id="B3">
          <title>DBT Period, Lu AF35700 20 mg</title>
          <description>Lu AF35700: 20 mg/day, encapsulated tablets, orally for 10 weeks</description>
        </group>
        <group group_id="B4">
          <title>DBT Period, Continued Treatment From PC Period</title>
          <description>Patients in this arm continued with the same treatment and dose as at the last visit of the PC Period. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="401"/>
            <count group_id="B2" value="235"/>
            <count group_id="B3" value="232"/>
            <count group_id="B4" value="230"/>
            <count group_id="B5" value="1098"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="11.05"/>
                    <measurement group_id="B2" value="42.6" spread="12.14"/>
                    <measurement group_id="B3" value="42.3" spread="11.44"/>
                    <measurement group_id="B4" value="43.2" spread="11.19"/>
                    <measurement group_id="B5" value="43" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="421"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="177"/>
                    <measurement group_id="B5" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="178"/>
                    <measurement group_id="B5" value="719"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PANSS total score</title>
          <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.25" spread="11.21"/>
                    <measurement group_id="B2" value="96.96" spread="9.17"/>
                    <measurement group_id="B3" value="98.23" spread="9.29"/>
                    <measurement group_id="B4" value="98.40" spread="9.84"/>
                    <measurement group_id="B5" value="97.6" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S score</title>
          <description>CGI-S provides the clinician’s impression of the patient’s current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient’s current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.82" spread="0.60"/>
                    <measurement group_id="B2" value="4.88" spread="0.59"/>
                    <measurement group_id="B3" value="5.00" spread="0.57"/>
                    <measurement group_id="B4" value="4.90" spread="0.53"/>
                    <measurement group_id="B5" value="4.89" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Randomization to Week 10 in Positive and Negative Syndrome Scale (PANSS) Total Score</title>
        <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Lu AF35700: 10 mg/day, encapsulated tablets, orally for 10 weeks</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Lu AF35700: 20 mg/day, encapsulated tablets, orally for 10 weeks</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period (olanzapine or risperidone)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization to Week 10 in Positive and Negative Syndrome Scale (PANSS) Total Score</title>
          <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.01" spread="0.96"/>
                    <measurement group_id="O2" value="-8.22" spread="0.98"/>
                    <measurement group_id="O3" value="-9.90" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean changes from Randomization in PANSS total score was analysed using a MMRM approach. The model included the fixed, categorical effects of treatment, country, week, treatment-by-week interaction, PC Period treatment, PC Period treatment-by-week interaction, and the continuous covariates of Randomization score and Randomization score-by-week interaction with an unstructured covariance structure to model the within-patient errors.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9196</p_value>
            <p_value_desc>Multiplicity adjustment was planned for the testing of the primary enpoint, but was not applied since all p-values&gt;0.05.</p_value_desc>
            <method>Mixed model repeated measures</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean changes from Randomization in PANSS total score was analysed using a MMRM approach. The model included the fixed, categorical effects of treatment, country, week, treatment-by-week interaction, PC Period treatment, PC Period treatment-by-week interaction, and the continuous covariates of Randomization score and Randomization score-by-week interaction with an unstructured covariance structure to model the within-patient errors.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1474</p_value>
            <p_value_desc>Multiplicity adjustment was planned for the testing of the primary endpoint, but was not applied since all p-values&gt;0.05.</p_value_desc>
            <method>Mixed model repeated measures</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>3.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization to Week 10 in PSP Total Personal and Social Performance (PSP) Total Score</title>
        <description>PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. It consists of 4 items: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviours. Each items were assessed on a 6-point scale, from 1 (absent) to 6 (very severe). PSP score was calculated as sum of all the items on the scale and ranged from 4 to 100. A higher score represents more severe functional impairment.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization to Week 10 in PSP Total Personal and Social Performance (PSP) Total Score</title>
          <description>PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. It consists of 4 items: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviours. Each items were assessed on a 6-point scale, from 1 (absent) to 6 (very severe). PSP score was calculated as sum of all the items on the scale and ranged from 4 to 100. A higher score represents more severe functional impairment.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="0.96"/>
                    <measurement group_id="O2" value="3.23" spread="0.98"/>
                    <measurement group_id="O3" value="3.94" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean changes from Randomization in PSP score was analysed using a MMRM approach. The model included the fixed, categorical effects of treatment, country, week, treatment-by-week interaction, PC Period treatment, PC Period treatment-by-week interaction, and the continuous covariates of Randomization score and Randomization score-by-week interaction with an unstructured covariance structure to model the within-patient errors.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2998</p_value>
            <p_value_desc>Multiplicity adjustment was planned for the testing of the primary endpoint, but was not applied since all p-values&gt;0.05.</p_value_desc>
            <method>Mixed model repeated measures</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>2.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The mean changes in PSP score was analysed using a MMRM approach. The model included the fixed, categorical effects of treatment, country, week, treatment-by-week interaction, PC Period treatment, PC Period treatment-by-week interaction, and the continuous covariates of Randomization score and Randomization score-by-week interaction with an unstructured covariance structure to model the within-patient errors.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4478</p_value>
            <p_value_desc>Multiplicity adjustment was planned for the testing of the primary endpoint, but was not applied since all p-values&gt;0.05.</p_value_desc>
            <method>Mixed model repeated measures</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.54</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization to Week 10 in Global Clinical Impression - Severity of Illness (CGI-S) Score</title>
        <description>CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization to Week 10 in Global Clinical Impression - Severity of Illness (CGI-S) Score</title>
          <description>CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.06"/>
                    <measurement group_id="O2" value="-0.54" spread="0.06"/>
                    <measurement group_id="O3" value="-0.57" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response at Week 10, Defined as ≥20% Reduction in PANSS Total Score, PANSS (Positive and Negative Syndrome Scale) Total Score ≤70, CGI-S (Clinical Global Impression Scale - Severity of Illness) Score &lt;4</title>
        <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.
The Clinical Global Impression scale - severity of illness (CGI-S) is administered by the investigator. The patient is rated on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). A reduction in scale indicates improvement.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 10, Defined as ≥20% Reduction in PANSS Total Score, PANSS (Positive and Negative Syndrome Scale) Total Score ≤70, CGI-S (Clinical Global Impression Scale - Severity of Illness) Score &lt;4</title>
          <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.
The Clinical Global Impression scale - severity of illness (CGI-S) is administered by the investigator. The patient is rated on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). A reduction in scale indicates improvement.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response at Week 10, Defined as ≥20% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</title>
        <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 10, Defined as ≥20% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</title>
          <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response at Week 10, Defined as ≥30% Reduction in PANSS Total Score From Randomization</title>
        <description>Positive and Negative Syndrome Scale (PANSS) total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 10, Defined as ≥30% Reduction in PANSS Total Score From Randomization</title>
          <description>Positive and Negative Syndrome Scale (PANSS) total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response at Week 10, Defined as ≥40% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</title>
        <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 10, Defined as ≥40% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</title>
          <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response at Week 10, Defined as ≥50% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</title>
        <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
        <time_frame>From Randomization to Week 10</time_frame>
        <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 10 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O2">
            <title>DBT Period, Lu AF35700 20 mg</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
Lu AF35700: 20 mg/day, encapsulated tablets, orally</description>
          </group>
          <group group_id="O3">
            <title>DBT Period, Continued Treatment From PC Period</title>
            <description>Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
Risperidone: 4-6 mg/day, encapsulated tablets, orally
Olanzapine: 15-20 mg/day, encapsulated tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Response at Week 10, Defined as ≥50% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization</title>
          <description>PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.</description>
          <population>Only patients randomized to receive double-blind treatment in the DBT Period are analysed. Patients randomized into the DBT period with risperidone or olanzapine were analyzed as one arm independent of treatment. Overall Number of Participants Analysed is number of patients in the FAS with a week 10 observation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prospective Confirmation (PC) Period, Risperidone</title>
          <description>Patients not randomized to double-blind treatment</description>
        </group>
        <group group_id="E2">
          <title>PC Period, Olanzapine</title>
          <description>Patients not randomized to double-blind treatment</description>
        </group>
        <group group_id="E3">
          <title>Double Blind Treatment (DBT) Period, Lu AF35700 10 mg</title>
          <description>Lu AF35700: 10 mg/day, encapsulated tablets, orally for 10 weeks</description>
        </group>
        <group group_id="E4">
          <title>DBT Period, Lu AF35700 20 mg</title>
          <description>Lu AF35700: 20 mg/day, encapsulated tablets, orally for 10 weeks</description>
        </group>
        <group group_id="E5">
          <title>DBT Period, Continued Treatment From PC Period</title>
          <description>Patients in this arm continued with the same treatment and dose as at the last visit of the PC Period. This arm is analyzed as one single treatment arm independent on which treatment was administered (olanzapine or risperidone).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA - 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Psychosocial support</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA - 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="235"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="235"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="235"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="708"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="384"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Email contact via</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+4536301311</phone>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

